Ranbaxy to acquire the unbranded generic business of GlaxSmithKline in Italy
Commenting on the acquisition, Malvinder Mohan Singh, CEO and MD, Ranbaxy Laboratories Ltd., said, "This acquisition of the Allen Generic business from GSK will fast track Ranbaxy's growth plans in Italy. This product portfolio complements Ranbaxy's own pipeline of products for the Italian market and will enable the Company to utilise opportunities arising from future patent expiries."
Ranbaxy's Italian operation, Ranbaxy Italia S.p.A., was incorporated in September 2005. It is currently engaged in filing Ranbaxy's portfolio of generic products with the Italian Health Authorities and plans to launch this portfolio over the coming years. Ranbaxy plans to launch its first product, 'Sertralina Ranbaxy', in May, 2006.
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.